Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: natural killer cells
DRUG: cyclophosphamide
DRUG: fludarabine phosphate
PROCEDURE: allogeneic hematopoietic stem cell transplantation
RADIATION: total body irradiation
BIOLOGICAL: Thymoglobulin
DRUG: Cyclosporin A
DRUG: cyclophosphamide
DRUG: fludarabine phosphate

Sponsor

Masonic Cancer Center, University of Minnesota